| Literature DB >> 36079206 |
Kaffayatullah Khan1, Babatunde Abiodun Salami2, Arshad Jamal3, Muhammad Nasir Amin1, Muhammad Usman4, Majdi Adel Al-Faiad1, Abdullah M Abu-Arab1, Mudassir Iqbal5.
Abstract
The depletion of natural resources of river sand and its availability issues as a construction material compelled the researchers to use manufactured sand. This study investigates the compressive strength of concrete made of manufactured sand as a partial replacement of normal sand. The prediction model, i.e., gene expression programming (GEP), was used to estimate the compressive strength of manufactured sand concrete (MSC). A database comprising 275 experimental results based on 11 input variables and 1 target variable was used to train and validate the developed models. For this purpose, the compressive strength of cement, tensile strength of cement, curing age, Dmax of crushed stone, stone powder content, fineness modulus of the sand, water-to-binder ratio, water-to-cement ratio, water content, sand ratio, and slump were taken as input variables. The investigation of a varying number of genetic characteristics, such as chromosomal number, head size, and gene number, resulted in the creation of 11 alternative models (M1-M11). The M5 model outperformed other created models for the training and testing stages, with values of (4.538, 3.216, 0.919) and (4.953, 3.348, 0.906), respectively, according to the results of the accuracy evaluation parameters root mean square error (RMSE), mean absolute error (MAE), and coefficient of determination (R2). The R2 and error indices values revealed that the experimental and projected findings are in extremely close agreement. The best model has 200 chromosomes, 8 head sizes, and 3 genes. The mathematical expression achieved from the GEP model revealed that six parameters, namely the compressive and tensile strength of cement, curing period, water-binder ratio, water-cement ratio, and stone powder content contributed effectively among the 11 input variables. The sensitivity analysis showed that water-cement ratio (46.22%), curing period (25.43%), and stone powder content (13.55%) were revealed as the most influential variables, in descending order. The sensitivity of the remaining variables was recorded as w/b (11.37%) > fce (2.35%) > fct (1.35%).Entities:
Keywords: compressive strength; concrete; gene expression programing; manufactured sand
Year: 2022 PMID: 36079206 PMCID: PMC9456692 DOI: 10.3390/ma15175823
Source DB: PubMed Journal: Materials (Basel) ISSN: 1996-1944 Impact factor: 3.748
Descriptive statistics of the input data used for the development of models.
| Descriptive Statistics | FM | W | S | Slp (mm) | Compressive Strength | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 48.34 | 8.26 | 82.11 | 31.37 | 7.79 | 3.06 | 0.43 | 0.47 | 172.68 | 36.74 | 87.79 | 54.24 |
| Standard Error | 0.23 | 0.03 | 6.18 | 0.73 | 0.28 | 0.02 | 0.01 | 0.00 | 1.26 | 0.26 | 3.65 | 0.96 |
| Median | 46.80 | 8.00 | 28.00 | 31.50 | 7.00 | 3.19 | 0.45 | 0.45 | 180.00 | 36.00 | 60.00 | 55.40 |
| Mode | 46.80 | 8.00 | 28.00 | 31.50 | 13.00 | 3.34 | 0.45 | 0.45 | 180.00 | 36.00 | 50.00 | 68.00 |
| Standard Deviation | 3.77 | 0.53 | 102.49 | 12.16 | 4.64 | 0.25 | 0.08 | 0.08 | 20.96 | 4.33 | 60.60 | 16.00 |
| Sample Variance | 14.20 | 0.28 | 10,504.05 | 147.95 | 21.53 | 0.06 | 0.01 | 0.01 | 439.22 | 18.73 | 3671.81 | 256.00 |
| Kurtosis | 0.36 | 0.23 | 1.54 | 11.31 | −0.94 | 0.24 | −0.93 | 0.53 | 6.41 | −0.75 | −0.37 | −0.72 |
| Skewness | 0.11 | 0.07 | 1.66 | 3.45 | 0.10 | −0.84 | −0.06 | 0.68 | −0.81 | 0.28 | 0.89 | −0.27 |
| Range | 17.00 | 2.50 | 385.00 | 60.00 | 20.00 | 1.04 | 0.31 | 0.36 | 187.00 | 16.00 | 249.00 | 68.80 |
| Minimum | 38.20 | 6.90 | 3.00 | 20.00 | 0.00 | 2.30 | 0.25 | 0.31 | 104.00 | 28.00 | 11.00 | 18.40 |
| Maximum | 55.20 | 9.40 | 388.00 | 80.00 | 20.00 | 3.34 | 0.56 | 0.67 | 291.00 | 44.00 | 260.00 | 87.20 |
| Count | 275 | 275 | 275 | 275 | 275 | 275 | 275 | 275 | 275 | 275 | 275 | 275.00 |
| Confidence Level (95.0%) | 0.45 | 0.06 | 12.17 | 1.44 | 0.55 | 0.03 | 0.01 | 0.01 | 2.49 | 0.51 | 7.19 | 1.90 |
Figure 1Details of variables used in the development of models.
Pearson’s correlation coefficient among the variables used in the development of models.
|
|
|
|
|
|
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| 1 | |||||||||||
|
| 0.88 | 1 | ||||||||||
|
| −0.26 | −0.33 | 1 | |||||||||
|
| 0.20 | −0.04 | 0.01 | 1 | ||||||||
|
| −0.17 | −0.12 | 0.08 | 0.45 | 1 | |||||||
|
| −0.25 | −0.07 | 0.06 | −0.20 | −0.08 | 1 | ||||||
|
| −0.13 | −0.05 | 0.10 | 0.30 | 0.46 | 0.23 | 1 | |||||
|
| 0.22 | 0.06 | −0.02 | 0.63 | 0.27 | −0.15 | 0.74 | 1 | ||||
|
| −0.34 | −0.12 | 0.13 | −0.61 | −0.04 | 0.35 | 0.12 | −0.41 | 1 | |||
|
| −0.03 | −0.03 | 0.09 | −0.37 | −0.22 | −0.04 | 0.42 | 0.36 | 0.21 | 1 | ||
|
| 0.06 | 0.08 | 0.02 | −0.27 | −0.37 | −0.06 | −0.19 | −0.03 | −0.10 | 0.29 | 1 | |
|
| −0.14 | −0.20 | 0.46 | −0.40 | −0.36 | −0.06 | −0.66 | −0.59 | 0.09 | −0.16 | 0.16 | 1 |
Figure 2Flowchart of the study.
Details of trials and their statistical evaluation using correlation and error indices.
| Trial No. | Used Variables | No. of Chromosomes | Head Size | Number of Genes | Constants per Gene | No. of Literals | Program Size | Training Dataset | Validation Dataset | Overall R2 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Best Fitness | RMSE | MAE | R2 | Best Fitness | RMSE | MAE | R2 | |||||||||
| 1 | 11 | 30 | 8 | 3 | 10 | 15 | 45 | 167.5 | 4.970 | 3.664 | 0.902 | 144.080 | 5.940 | 4.439 | 0.866 | 0.884 |
| 2 | 7 | 50 | 8 | 3 | 10 | 13 | 37 | 173.9 | 4.749 | 3.371 | 0.910 | 165.180 | 5.054 | 3.444 | 0.902 | 0.906 |
| 3 | 9 | 100 | 8 | 3 | 10 | 15 | 37 | 164.0 | 5.098 | 3.839 | 0.897 | 151.070 | 5.619 | 3.856 | 0.879 | 0.888 |
| 4 | 6 | 150 | 8 | 3 | 10 | 14 | 33 | 155.5 | 5.430 | 3.858 | 0.883 | 146.890 | 5.807 | 4.160 | 0.872 | 0.878 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 6 | 6 | 200 | 9 | 3 | 10 | 12 | 39 | 172.6 | 4.793 | 3.532 | 0.909 | 149.420 | 5.692 | 4.079 | 0.878 | 0.894 |
| 7 | 9 | 200 | 10 | 3 | 10 | 18 | 44 | 161.9 | 5.175 | 3.866 | 0.894 | 125.360 | 6.976 | 4.735 | 0.822 | 0.858 |
| 8 | 7 | 200 | 11 | 3 | 10 | 18 | 46 | 163.9 | 5.100 | 3.366 | 0.897 | 144.350 | 5.927 | 4.055 | 0.869 | 0.883 |
| 9 | 9 | 200 | 12 | 3 | 10 | 18 | 50 | 163.5 | 5.114 | 3.777 | 0.896 | 146.180 | 5.840 | 4.158 | 0.870 | 0.883 |
| 10 | 7 | 200 | 8 | 4 | 10 | 21 | 55 | 171.5 | 4.830 | 3.456 | 0.907 | 147.920 | 5.760 | 3.845 | 0.875 | 0.891 |
| 11 | 9 | 200 | 8 | 5 | 10 | 22 | 64 | 191.3 | 4.226 | 3.054 | 0.929 | 149.470 | 5.689 | 3.960 | 0.877 | 0.903 |
Figure 3Effect of genetic variables on the performance of GEP models.
Figure 4Comparison of overall (a) R and (b) MAE for the trials undertaken in this study.
Figure 5Comparison of the trials using Taylor diagram for (a) training data and (b) validation data.
Figure 6Comparison of regression slope for trial No. 5.
Figure 7Error Analysis for the optimized trial.
Figure 8Predicted/experimental ratio for the optimized trial No. 5. (a) Training dataset (b) Validation dataset.
Figure 9Expression tree generated from GEP model for optimized trial.
Figure 10Sensitivity analysis of the developed model.
Figure 11Parametric analysis of the optimized model (a) f (b) f (c) T (d) SPC (e) w/b (f) w/c.